Clinical Trial Update: Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Harvoni in patients with decompensated cirrhosis due to Hepatitis C genotype 1; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis Decompensated
• Hepatitis C

Drugs mentioned

• HARVONI (Ledipasvir and Sofosbuvir)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatitis C, Chronic, Cirrhosis, Decompensated | Phase 3 | Status: COMPLETED